At the 2026 AAAAI Annual Meeting in Philadelphia, new data put a spotlight on a simple but powerful question:
If given a choice, would patients prefer a needle-free adrenaline spray over a traditional auto-injector? According to ALK’s latest study, the answer is clear.
88% of participants preferred EURneffy, the first approved needle-free, adrenaline-based nasal spray, over traditional adrenaline auto-injectors.
Anaphylaxis is not rare. It is sudden. It is life-threatening. And it demands immediate treatment. Adrenaline remains the recommended first-line therapy. Yet real-world data show worrying gaps:
The issue isn’t clinical efficacy. It’s usability. That’s the gap EURneffy aims to close.
This was a randomised crossover study involving 90 participants:
Participants:
The reasons were practical and psychological. Participants cited:
In fact:
Dr. Douglas P. Mack, pediatric allergy and immunology specialist and assistant clinical professor at McMaster University, noted that long-term familiarity does not automatically translate into real-world confidence.
Even participants with years of auto-injector experience still preferred the nasal option.
According to ALK, the findings highlight the need for clinicians and payers to consider treatment choice beyond clinical performance — including confidence, portability, and everyday usability.
EURneffy is a needle-free nasal adrenaline spray designed for emergency treatment of severe allergic reactions.
Key features include:
Under the brand name neffy, approvals include:
Indications cover adults and children based on weight thresholds.
Anaphylaxis can escalate within minutes. Access and willingness to act matter.
While adrenaline auto-injectors are clinically effective, established barriers remain:
This study suggests that addressing those everyday friction points may improve real-world readiness. Additional data from the EURneffy user study are expected at future congresses throughout 2026.
Anaphylaxis is a severe, systemic allergic reaction involving multiple organ systems. It can occur within minutes of allergen exposure and requires immediate medical intervention. Prompt adrenaline administration significantly reduces morbidity and mortality.
ALK is a global specialty pharmaceutical company focused exclusively on allergy. Its portfolio spans diagnosis and treatment of respiratory allergies and severe allergic reactions in both children and adults.